Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
398 - In the current consultation by Health Canada on the Guidance Document: Product Monograph Release Part I: Health Professional Information and Part II: Scientific Information, Health Canada proposes to remove references, as per the response to question 309 , what impact would removal of references have on the utilization of the study by companies if not listed in the PM?
-
Mention of a study in the PM bibliography has no influence on the PAAB review. Given this fact, the removal of the bibliography changes nothing from a PAAB review perspective. As a point of interest, PAAB code section 3.1.2 states that citation in the bibliography section of the Product Monograph does not indicate proof of acceptance by Health Canada.
